Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis.

BACKGROUND: Fluid overload is common in patients with diabetes and chronic kidney disease (DM and CKD; DMCKD) and can lead to structural and functional cardiac abnormalities including left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD). Fluid overload represents a crucial step in the pathophysiological pathways to chronic heart failure in patients with end-stage renal disease. We evaluated the impact of fluid overload on cardiac alterations in patients with diabetes and non-dialysis-dependent CKD stage 5 (DMCKD5-ND) without intrinsic heart disease.
METHODS: Bioimpedance spectroscopy, echocardiography, and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) measurement were performed in 135 consecutive patients on the same day. Patients were divided into groups by tertiles of overhydration/extracellular water (OH/ECW) per bioimpedance spectroscopy.
RESULTS: Fluid balance markers including OH/ECW and NT-proBNP were significantly higher in the LVDD+LVH group. OH/ECW and its exacerbation were positively associated with the ratio between early mitral inflow and annular early diastolic velocities (E/e' ratio) and left ventricular mass index (LVMI). The prevalence of LVH progressively increased across increasing tertiles of OH/ECW. In multiple regression analyses, OH/ECW as a continuous and categorical variable was independently associated with the E/e' ratio and LVMI after adjustment for multiple confounding factors.
CONCLUSIONS: Fluid overload was independently associated with LVDD and LVH in patients with DMCKD5-ND. Our study suggests that structural and functional cardiac abnormalities and volume status should be evaluated simultaneously in patients with early-stage DMCKD rather than only DMCKD5-ND, in addition to intensive blood pressure and glycemic control, regardless of evident cardiovascular disease.

Introduction

A component of diabetic cardiomyopathy (DCM) is asymptomatic progressive structural and functional remodeling in the heart of a patient with diabetes even in the absence of preceding factors such as coronary artery disease, hypertension, and valvular heart disease. DCM includes structural changes such as left ventricular hypertrophy (LVH) and functional changes such as left ventricular diastolic dysfunction (LVDD) or left ventricular systolic dysfunction. The prevalence of LVH in the general diabetic population is known to be up to 70% [1]. LVH and LVDD may be early manifestations of unrecognized diabetic cardiac impairment [2, 3]. A number of mechanisms have been proposed to elucidate the pathophysiology of DCM [4-8].

As renal function gradually decreases in patients with diabetes, cardiac abnormalities are at a greater risk of worsening. Nonetheless, less attention has been paid to left ventricular (LV) abnormalities in patients with diabetes and chronic kidney disease. Due to the complexity of chronic kidney disease (CKD)-related cardiovascular risk factors, such as albuminuria, anemia, secondary hyperparathyroidism, and fluid overload in addition to traditional cardiovascular risk factors such as age, sex, smoking, hypertension, hyperlipidemia, and hyperglycemia, it is very difficult to clearly identify the pathophysiology of type 2 diabetes mellitus and chronic kidney disease (DMCKD). LVH and LVDD each represent a manifestation of the effects of traditional risk factors and other CKD-related cardiovascular risk factors over time and often overlap with each other in patients with end-stage renal disease (ESRD).

Patients with type 2 diabetes mellitus (T2DM) have higher risks of cardiovascular events and mortality compared with patients without T2DM [9, 10]. Cardiovascular complications are the major cause of mortality and morbidity in patients with ESRD. Chronic fluid overload in ESRD is a strong risk factor for death [11]. Notwithstanding, there are no guidelines for a comprehensive therapeutic approach for cardiac abnormalities in patients with advanced DMCKD. Most of the therapeutic goals have been derived from clinical studies involving patients with no CKD or mild CKD and they merely suggest a therapeutic approach for each of the traditional or non-traditional cardiovascular risk factors.

Assessment of fluid overload in patients with DMCKD is important not only for short-term volume management but also for the long-term prevention of cardiovascular disease. This is because fluid overload represents a crucial step in the pathophysiological pathways to chronic heart failure in ESRD patients [12, 13]. Therefore, herein, we investigated the impact of actual fluid overload on LVH and LVDD development in patients with diabetes with non-dialysis-dependent CKD stage 5 (CKD5-ND) who were free of intrinsic heart disease.

Materials and methods

1. Patients and data collection

Since 2014, we have registered consecutive patients with stage 5 CKD (CKD5) to a bioimpedance cohort. All patients were hospitalized to plan their first dialysis treatment. Bioimpedance spectroscopy (BIS), echocardiography, and laboratory evaluation were performed on the same day at the time of enrollment, prior to dialysis.

Of the total cohort of patients, non-diabetic patients and those who did not undergo an echocardiographic examination were excluded from the analysis. A total of 29 patients with structural and functional cardiac abnormalities were excluded to reduce the effects of underlying heart disease that could cause LVH and/or LVDD. Patients who had a history of angina or myocardial infarction and patients who had findings of infarction on electrocardiography or had regional wall motion abnormalities on echocardiographic examination were considered as patients with coronary artery disease.

This study was conducted in accordance with the Declaration of Helsinki. This study was initiated after receiving approval (no. CR319143) from the Institutional Review Board of Yonsei University Wonju Severance Christian Hospital. All patients provided written inform consent prior to participation in the study. Therefore, the current study was a retrospective observational analysis of a prospective cohort database.

2. Conventional echocardiographic study

Echocardiography was performed in the harmonic imaging mode using a 3 MHz transducer and commercial ultrasound system (GE VividTM E9; GE Healthcare, Chicago, IL USA) prior to any dialysis treatment. The LV mass was calculated following the American Society of Echocardiography recommendations using following equation: where PWTd and SWTd are the posterior and septal wall thicknesses at end-diastole, respectively, and the LV end-diastolic dimension (LVEDD) is the M-mode LV dimension with the short axis view at end-diastole. To correct for body surface area, the LV mass index (LVMI) was calculated by dividing the LV mass by the body surface area (BSA), using the formula as follows: BSA = (0.007184 × weight0.425× height0.725) m2. The relative wall thickness (RWT) was calculated by the formula: RWT = (2 × PWTLVEDD). The left atrial (LA) dimension, LA volume index, LV end-diastolic volume (LVEDV), and LV ejection fraction (LVEF) were measured using the biplane modified Simpson’s rule, according to the previously mentioned recommendations. Transmitral inflow velocities were measured using pulsed-wave Doppler in the apical four-chamber view with the sample volume placed at the mitral valve leaflet tips. Transmitral early diastolic (E wave) velocities were measured. Tissue Doppler imaging in the apical four-chamber view was used to measure LV myocardial velocities, with the sample volume placed at the septal mitral annulus. We measured the peak early (e′) diastolic mitral annular velocity and calculated the E/e′ ratio [14]. LVH was defined as an LVMI >95 g/m2 in females and >115 g/m2 in males [15]. LVDD was defined as an E/e′ ratio >15 [16]. Echocardiography was performed by trained cardiologists who were completely blinded to the patient information.

3. Assessment of the volume status

Whole-body BIS was performed using the BCM system (Body Composition MonitoringTM, Fresenius Medical Care AG & Co., Bad Homburg vor der Höhe, Germany) prior to any dialysis treatment. Patients were in supine positions. Disposable electrode patches placed on the wrist and ankle were used for all measurements. Measurements were performed in the absence of metal and electronic devices on patients to minimize disruption. BCM utilizes alternating electric currents across 50 discrete frequencies covering the frequency spectrum from 5 to 1,000 kHz and measures each current’s impedance. A three compartment BIS model separates the body weight into normally hydrated lean tissue mass, normally hydrated adipose tissue mass, and fluid overload which is commonly described as the overhydration (OH) compartment [17]. Extracellular water (ECW), intracellular water, and total body water (TBW) were automatically calculated. The OH, which can be calculated from the difference between the actual measured ECW and the normally expected ECW, can be positive or negative [18]. Relative overhydration can be represented as OH/ECW. OH level, OH/ECW, ECW/TBW, and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) level were used as markers of fluid balance. In this study, volume status was treated as OH/ECW in the main analysis. The patient’s body mass index was recalculated for a corrected body mass index (cBMI) by considering fluid overload using the formula as follows: cBMI (kg/m2) = (body weight–OH)/height2.

4. Laboratory evaluations

All laboratory studies were performed before the first dialysis application. The high-sensitivity C-reactive protein (hs-CRP) level was measured using a Cobas 8000 Modular Analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The normal range for the hs-CRP is below 0.3 g/dL (3 g/L). The estimated glomerular filtration rate (eGFR) was calculated using the formula developed for the Modification of Diet in Renal Disease (MDRD) Study that is based on serum creatinine. The NT-proBNP level was measured using an electrochemiluminescence immunoassay (ECLIA) using the Modular Analytics E170 System (Roche Diagnostics, GmbH, Mannheim, Germany). The analytical measurement range for NT-proBNP was from 5 to 35,000 pg/mL. The patients were divided into three groups in accordance with the tertiles of NT-proBNP for the regression analysis.

5. Statistical analysis

Categorical variables were reported as frequencies and percentages, and continuous variables were reported as means with standard deviations or medians with interquartile ranges, as appropriate. All patients were classified into four groups according to the phenotypes of cardiac impairment (control patients with CKD5 but without cardiac impairment, and those with LVDD, LVH, and LVDD+LVH). All patients were also divided into three groups by tertile of OH/ECW for an analysis. Patient characteristics between groups were tested with a chi-squared test, Fisher’s exact test, analysis of variance (ANOVA) with post hoc Bonferroni correction, and a Kruskal–Wallis test. A linear-by-linear association method and a Jonckheere-Terpstra trend test were used for analyzing trends in the OH/ECW tertiles. We first performed stepwise linear regression analyses to identify the potential determinants of E/e′ ratio and LVMI adjusted for age, hs-CRP, albumin, phosphorus, and eGFR. We then performed multiple linear regression analyses to explore the association of E/e′ ratio and LVMI with the identified determinants. OH/ECW was considered as both a continuous and a categorical variable in the multivariate linear regression analyses. All analyses were performed using IBM SPSS Statistics software (version 23.0; IBM Corporation, Armonk, NY USA). Graphs were generated with Prism software (version 5.02; GraphPad Software, San Diego, CA USA). Statistically significant differences were defined as those having P-values <0.05.

Results

1. Characteristics of the study patients

After the application of the exclusion criteria, a total of 135 patients (control patients with CKD5, n = 35; LVDD, n = 21; LVH, n = 30; LVDD+LVH, n = 49) were analyzed (Fig 1). The mean age of male and female patients was 59.53 ± 12.29 years and 61.11 ± 10.80 years, respectively. Females accounted for 40% (n = 54) of all patients. The mean eGFR was 7.11 ± 2.39 mL/min/1.73 m2. In the present study, fluid overload was present in 101 patients (74.81%) when defined as OH/ECW over 7%, whereas severe fluid overload defined as OH/ECW over 15% was present in 77 patients (57.04%).

Fig 1

Flow diagram of patient selection in this study.

The clinical characteristics of each group according to the left ventricular abnormalities are presented in Table 1. Patients with diastolic dysfunction and hypertrophy had lower levels of eGFR and albumin, while markers of fluid balance such as OH, OH/ECW, ECW/TBW, and NT-proBNP were significantly higher than in any of the other groups. The median (interquartile range [IQR]) for OH/ECW and NT-proBNP were 17.40% (6.90–28.10%) and 2,842 (674–8,029) pg/mL, respectively.

Table 1

Comparisons of demographics, serum chemistry, echocardiographic findings, and volume status between the groups according to the left ventricular abnormalities.

Variables	Control patients with CKD5 (n = 35)	LVDD (n = 21)	LVH (n = 30)	LVDD+LVH (n = 49)	P-value
Age, years	59.89±11.29	60.10±11.55	59.30±11.17	60.92±12.64	0.944
<65 years	21 (25.0%)	14 (16.7%)	20 (23.8%)	29 (34.5%)	0.874
≥65 years	14 (27.5%)	7 (13.7%)	10 (19.6%)	20 (39.2%)
Sex
Male	27 (33.3%)	14 (17.3%)	20 (24.7%)	20 (24.7%)	0.005
Female	8 (14.8%)	7 (13.0%)	10 (18.5%)	29 (53.7%)
SBP, mmHg	140.19±22.73	145.52±16.84	142.21±15.74	149.83±15.74	0.098
DBP, mmHg	83.32±11.54	79.14±10.33	77.90±8.61	79.96±9.78	0.178
cBMI, kg/m2	23.44±4.11	25.24±4.09	24.06±4.38	24.08±4.20	0.497
LAD, cm	4.33±0.42	4.68±0.49	4.61±0.40	4.84±0.44	<0.001
LAVI, mL/m2	30.66±6.46	34.19±8.23	37.60±7.37	43.14±10.97	<0.001
E/e′ ratio	11.60±2.53	17.35±1.31	13.01±1.96	21.00±5.27	<0.001
LVEDD, cm	5.09±0.56	5.34±0.43	5.53±0.53	5.47±0.48	0.002
LVEDV, mL	127.69±27.96	138.91±25.36	152.10±33.45	145.18±36.38	0.018
LVMI, g/m2	90.97±14.43	99.76±10.22	128.17±16.83	127.41±19.42	<0.001
RWT	0.35±0.06	0.33±0.04	0.37±0.05	0.37±0.06	0.037
LVEF, %	63.13±4.73	62.67±5.56	63.87±6.26	63.39±5.01	0.878
NT-proBNP, pg/mL*	712 (293–6,334)	886 (565–2,847)	3,299 (1,186–7,305)	7,413 (2,589–19,247)	<0.001
hs-CRP, mg/dL	1.62±2.88	0.54±1.05	0.95±2.74	1.76±3.74	0.395
iPTH, pg/mL	228.17±114.92	315.63±198.96	285.31±137.79	282.15±168.87	0.190
HbA1C, %	7.22±2.08	7.21±2.14	6.63±1.10	6.91±1.41	0.514
Hemoglobin, g/dL	9.45±1.35	9.30±1.26	9.03±1.33	8.85±1.13	0.165
Total protein, g/dL	6.30±0.86	6.54±0.86	5.87±0.70	5.88±0.71	0.002
Albumin, g/dL	3.54±0.58	3.78±0.51	3.29±0.55	3.20±0.51	<0.001
Total cholesterol, mg/dL	143.57±41.61	140.19±36.00	148.35±41.03	152.10±44.38	0.671
HDL-C, mg/dL	39.24±14.64	36.57±13.04	39.14±11.56	38.55±12.54	0.887
LDL-C, mg/dL	76.00±35.44	76.57±30.59	85.52±36.45	87.32±38.83	0.446
Triglyceride, mg/dL	143.00±71.47	138.43±56.35	127.45±48.31	129.33±45.65	0.617
Calcium, mg/dL	8.04±0.88	8.21±0.98	7.59±1.02	7.57±0.85	0.012
Phosphate, mg/dL	5.54±1.65	5.40±1.03	6.11±1.60	6.22±1.28	0.053
eGFR, mL/min/1.73 m2	8.01±2.63	7.55±2.37	7.02±2.35	6.34±2.01	0.011
OH, liters	2.52±3.11	2.07±1.94	3.53±2.40	4.98±3.72	<0.001
OH/ECW, %	12.88±14.37	11.71±10.70	18.57±9.60	25.06±14.25	<0.001
ECW/TBW	0.49±0.04	0.50±0.04	0.51±0.03	0.54±0.04	<0.001

* Kruskal–Wallis test; median (interquartile range).

cBMI, corrected body mass index; DBP, diastolic blood pressure; ECW, extracellular water; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; iPTH, intact parathyroid hormone; LAD, left atrial dimension; LAVI, left atrial volume index; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVDD, left ventricular diastolic dysfunction; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; OH, overhydration; RWT, relative wall thickness; SBP, systolic blood pressure; TBW, total body water.

The clinical characteristics of the patients according to the tertiles of OH/ECW are presented in Table 2. Compared with patients in the first tertile of OH/ECW, the mean age for those in the third tertile was significantly lower. The eGFR, hemoglobin, albumin, and calcium levels were lower for those in the third tertile than for those in the first tertile. There was a trend of higher levels of phosphorus, hs-CRP, and NT-proBNP across increasing tertiles of OH/ECW. Exacerbation of the OH/ECW was significantly associated with echocardiographic findings including LAD, LAVI, E/e′ ratio, and LVMI. By running a post hoc test, the E/e′ ratio was significantly higher for those in the third tertile than in the first and second tertiles. Second and third tertile groups had significantly higher levels of LVMI than those in the first tertile group. There was no difference in LVEF between the three groups (Fig 2).

Table 2

Comparisons of demographics, serum chemistry, echocardiographic findings, and volume status according to the OH/ECW tertiles.

Variables	OH/ECW (%)			P-value	P for trend#
	Tertile 1	Tertile 2	Tertile 3
Age, years	63.12±9.07	60.46±11.30	56.11±13.54	0.018	0.005
<65 years	24 (28.9%)	25 (30.1%)	34 (41.0%)	0.063	0.038
≥65 years	19 (39.6%)	19 (39.6%)	10 (20.8%)
Sex
Male	23 (29.1%)	32 (40.5%)	24 (30.4%)	0.118	0.931
Female	20 (38.5%)	12 (23.1%)	20 (38.5%)
SBP, mmHg	139.14±18.60	145.98±18.98	149.46±17.23	0.031	0.012
DBP, mmHg	77.11±8.99	81.07±10.00	82.48±10.95	0.039	0.027
cBMI, kg/m2	25.03±3.62	24.87±4.41	22.37±4.05	0.003	0.001
LAD, cm	4.46±0.43	4.64±0.45	4.75±0.49	0.017	0.001
LAVI, mL/m2	32.05±8.32	36.89±8.12	42.11±10.56	<0.001	<0.001
E/e′ ratio	14.72±4.09	15.18±4.72	18.81±6.36	<0.001	0.002
LVEDD, cm	5.22±0.44	5.50±0.62	5.40±0.49	0.048	0.124
LVEDV, mL	129.76±32.00	151.36±33.58	142.30±30.67	0.008	0.107
LVMI, g/m2	102.47±15.67	119.23±24.81	119.82±24.54	<0.001	<0.001
RWT	0.34±0.05	0.36±0.06	0.37±0.06	0.164	0.029
LVEF, %	63.26±4.45	62.55±5.03	64.11±5.90	0.364	0.560
NT-proBNP, pg/mL*	632 (380–1,555)	3,137 (1,056–7,350)	8,025 (4,398–18,736)	<0.001	<0.001
hs-CRP, mg/dL	0.56±1.01	1.33±3.10	2.01±3.86	0.107	0.004
iPTH, pg/mL	290.59±168.81	286.37±170.41	253.71±131.23	0.496	0.333
HbA1C, %	7.40±2.00	6.87±1.38	6.72±1.61	0.174	0.055
Hemoglobin, g/dL	9.61±1.35	9.06±1.19	8.79±1.02	0.006	0.005
Total protein, g/dL	6.74±0.68	6.00±0.55	5.54±0.72	<0.001	<0.001
Albumin, g/dL	3.82±0.43	3.35±0.42	3.02±0.55	<0.001	<0.001
Total cholesterol, mg/dL	147.21±39.91	138.96±33.46	154.55±49.80	0.217	0.627
HDL-C, mg/dL	39.00±13.38	36.12±11.13	40.54±14.20	0.280	0.592
LDL-C, mg/dL	79.95±33.27	77.21±31.15	89.28±43.45	0.276	0.477
Triglyceride, mg/dL	144.12±61.93	131.96±53.75	123.07±49.05	0.206	0.120
Calcium, mg/dL	8.24±1.00	7.63±0.89	7.49±0.78	<0.001	<0.001
Phosphate, mg/dL	5.52±1.43	6.02±1.39	6.10±1.46	0.126	0.023
eGFR, mL/min/1.73 m2	8.12±2.29	6.82±2.39	6.42±2.03	0.002	0.001
OH, liters	0.52±0.76	2.96±0.76	7.12±2.81	<0.001	<0.001
OH/ECW, %	3.24±5.03	17.01±3.29	34.37±7.44	<0.001	<0.001
ECW/TBW	0.47±0.03	0.51±0.02	0.56±0.03	<0.001	<0.001

* Kruskal–Wallis test; median (interquartile range)

# P-values obtained by the linear-by-linear association method or Jonckheere–Terpstra test.

OH/ECW tertiles 1, 2, and 3 correspond to <10.60, 10.60–24.68, and >24.68%, respectively.

cBMI, corrected body mass index; DBP, diastolic blood pressure; ECW, extracellular water; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; hs-CRP high-sensitivity C reactive protein; iPTH, intact parathyroid hormone; LAD, left atrial dimension; LAVI, left atrial volume index; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; OH, overhydration; RWT, relative wall thickness; SBP, systolic blood pressure; TBW, total body water.

Fig 2

Left ventricular structural and functional alterations and glomerular filtration rate according to the tertile distribution of OH/ECW.

OH/ECW was positively associated with LA dimension (r = 0.236; P = 0.007), LAVI (r = 0.408; P < 0.001), E/e′ ratio (r = 0.344; P < 0.001), LVEDV (r = 0.178; P = 0.042), RWT (r = 0.172; P = 0.049), and LVMI (r = 0.359; P < 0.001). While OH/ECW was not significantly associated with LVEDD, LVEDV and LVEF, OH/ECW was positively associated with hs-CRP (r = 0.219; P = 0.017) and inversely associated with cBMI (r = -0.280; P = 0.001), eGFR (r = -0.302; P < 0.001), and serum calcium levels (r = -0.367; P < 0.001). There was a marginally significant association between OH/ECW and SBP (r = 0.171; P = 0.051).

LVDD was present in 70 patients (51.85%) (S1 Table). LVH was present in 79 patients (58.52%) (S2 Table). The prevalence of LVDD was 48.8%, 38.6%, and 68.2% and for LVH was 35.0%, 65.9%, and 72.7% in OH/ECW tertiles 1, 2, and 3, respectively. The prevalence of LVH progressively increased across increasing tertiles of OH/ECW (P for trend <0.001) (Fig 3). However, the P-value for trend of LVDD prevalence was not significant (P for trend = 0.070).

Fig 3

Comparison of the percentage distribution of subjects according to the tertile distribution of OH/ECW.

A) LVDD; chi-squared test, P = 0.019, B) LVH; chi-squared test, P = 0.001.

2. Determining factors of E/e′ ratio and LVMI

Stepwise linear regression analyses showed that cBMI, OH/ECW, being female, and SBP were shown to be significantly associated with E/e′ ratio, after adjustment for clinical confounding factors including age, hs-CRP, albumin, phosphorus, and eGFR. Meanwhile, cBMI, OH/ECW, and serum calcium levels were significantly associated with LVMI after adjustment for confounding factors (S3 Table).

3. Multiple linear regression analyses

When evaluating OH/ECW as a continuous variable in a multiple linear regression analysis, the association of OH/ECW with E/e′ ratio remained statistically significant in all three models. When evaluating OH/ECW and NT-proBNP as categorical variables for further analysis, both showed significant β coefficients in the third tertile compared to the reference group (Table 3). In addition, similar associations between OH/ECW as a continuous variable and LVMI remained statistically significant in fully adjusted models. When evaluating OH/ECW and NT-proBNP as categorical variables, both parameters also showed significant associations with LVMI (Table 4). All of these associations suggest that OH/ECW and NT-proBNP are contributing factors for LVDD and LVH development in patients with diabetes and CKD5-ND who are free of intrinsic heart disease.

Table 3

Factors independently associated with E/e′ ratio.

	Unadjusted	Model 1	Model 2	Model 3
	Β (95% CI)	Β (95% CI)	Β (95% CI)	Β (95% CI)
OH/ECW analyzed as a continuous variable
OH/ECW, %	0.135 (0.071, 0.199)	0.148 (0.084, 0.211)	0.152 (0.088, 0.216)	0.134 (0.057, 0.211)
OH/ECW analyzed in tertiles
OH/ECW, %
tertile 1	Reference	Reference	Reference	Reference
tertile 2	0.458 (-1.729, 2.644)	1.168 (-0.960, 3.297)	0.783 (-1.262, 2.828)	0.084 (-2.238, 2.405)
tertile 3	4.083 (1.896, 6.269)	4.454 (2.295, 6.613)	4.404 (2.206, 6.601)	3.539 (0.973, 6.105)
NT-proBNP analyzed in tertiles
NT-proBNP, pg/mL
tertile 1	Reference	Reference	Reference	Reference
tertile 2	1.820 (-0.352, 3.991)	1.466 (-0.642, 3.574)	1.170 (-0.911, 3.250)	0.819 (-1.595, 3.234)
tertile 3	3.781 (1.610, 5.953)	3.756 (1.662, 5.850)	3.663 (1.537, 5.789)	2.938 (0.199, 5.676)

Model 1: Adjusted for age and sex.

Model 2: Adjusted for age, sex, cBMI, and SBP.

Model 3: Adjusted for age, sex, cBMI, SBP, calcium, eGFR, and hs-CRP.

OH/ECW tertiles 1, 2, and 3 correspond to <10.60, 10.60–24.68, and >24.68%, respectively.

NT-proBNP tertiles 1, 2, and 3 correspond to <1,143, 1,143–7,087, and >7,087 pg/mL, respectively.

B, β coefficient; cBMI, corrected body mass index; CI, confidence interval; ECW, extracellular water; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C reactive protein; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; OH, overhydration; SBP, systolic blood pressure.

Table 4

Factors independently associated with left ventricular mass index.

	Unadjusted	Model 1	Model 2	Model 3
	Β (95% CI)	Β (95% CI)	Β (95% CI)	Β (95% CI)
OH/ECW analyzed as a continuous variable
OH/ECW, %	0.604 (0.330, 0.878)	0.684 (0.402, 0.966)	0.725 (0.430, 1.020)	0.525 (0.157, 0.893)
OH/ECW analyzed in tertiles
OH/ECW, %
tertile 1	Reference	Reference	Reference	Reference
tertile 2	16.762 (7.374, 26.151)	16.389 (6.882, 25.986)	15.610 (6.060, 25.159)	12.194 (1.374, 23.013)
tertile 3	17.353 (7.965, 26.742)	14.412 (9.218, 28.505)	19.113 (8.852, 29.373)	13.225 (1.266, 25.183)
NT-proBNP analyzed in tertiles
NT-proBNP, pg/mL
tertile 1	Reference	Reference	Reference	Reference
tertile 2	17.911 (8.919, 26.902)	18.591 (9.639, 27.544)	19.264 (10.213, 28.315)	16.494 (5.881, 27.107)
tertile 3	21.155 (12.164, 30.146)	21.353 (12.459, 30.248)	23.098 (13.849, 32.347)	15.981 (3.944, 28.018)

Model 1: Adjusted for age and sex.

Model 2: Adjusted for age, sex, cBMI, and SBP.

Model 3: Adjusted for age, sex, cBMI, SBP, calcium, eGFR, and hs-CRP.

OH/ECW tertiles 1, 2, and 3 correspond to <10.60, 10.60–24.68, and >24.68%, respectively.

NT-proBNP tertiles 1, 2, and 3 correspond to <1,143, 1,143–7,087, and >7,087 pg/mL, respectively.

B, β coefficient; cBMI, corrected body mass index; CI, confidence interval; ECW, extracellular water; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C reactive protein; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; OH, overhydration; SBP, systolic blood pressure.

Discussion

DCM was introduced by Rubler et al. and is known as a risk factor for heart failure [19]. Prior to the emergence of clinical heart failure, DCM is associated with LVH, cardiac remodeling, advancing diastolic dysfunction, and subclinical left ventricular systolic impairment [20].

In-depth studies have been conducted on who should undergo screening in relation to the progression of DCM in patients with diabetes with normal kidney function. However, there has not been much research on the diagnostic approach for patients with DMCKD only. Cardiovascular disease is the leading cause of complications in diabetes. CKD is another major risk factor for cardiovascular morbidity and mortality regardless of the cause. Given that diabetes is the most common cause of ESRD, cardiovascular complications are the major cause of mortality and morbidity in patients with DMCKD. As the pathophysiology of DMCKD is so complex and most cases have more than one risk factor [21], it may be difficult to determine the exact cause of cardiac impairment in patients with advanced DMCKD.

LVDD is regarded as the first functional change of subclinical cardiac alterations in patients with diabetes without renal insufficiency [3, 22–24], and the prevalence of LVH in diabetes is higher [1]. LVDD is also common in CKD regardless of the cause [25, 26]. In patients with CKD, the mechanism of LVDD is complex and mainly associated with LVH, which is a physiological adaptive response to pressure and/or volume overload [27, 28]. LVH is intrinsically arrhythmogenic, leads to diastolic heart failure, and causes ischemia and sudden death [29]. Although hypertension is not a reliable biomarker of volume overload in patients with ESRD, the effect of volume overload on blood pressure is crucial. A higher level of ECW was an independent determinant of both resistant and uncontrolled hypertension during CKD [30]. Blood pressure still plays a major role in inducing LV remodeling in CKD. Therefore, our results support that fluid overload is a considerable risk factor for functional and structural LV alteration. The poor prognosis of fluid overload is mainly explained by the link with cardiovascular effects such as LVH, LV systolic and diastolic dysfunction, pulmonary hypertension, and increased aortic stiffness [31]. Therefore, the need for clinical evaluation to diagnose cardiac alterations in the early stages of CKD is emphasized [32].

In our study, there was a trend of higher levels of E/e′ ratio, LVMI, and NT-proBNP across increasing tertiles of OH/ECW. Relative overhydration (OH/ECW) was independently associated with E/e′ ratio and LVMI in a multiple linear regression. NT-proBNP, a marker for fluid overload in our study, showed significantly different levels between patients with and without cardiac abnormalities, such as LVDD and LVH, respectively. It is unclear whether NT-proBNP itself reflects volume status or whether it is a byproduct of structural and functional alterations of the myocardium due to fluid overload in our study, even though NT-proBNP is known to be associated with LVDD [33] and LVH [34]. The diagnostic value of NT-proBNP in patients with CKD is limited because decreased renal function affects NT-proBNP levels and there are no optimal cut-off values for diagnosis confirmation [35]. In addition, NT-proBNP levels are influenced by the presence of diabetes [36].

In recent years, many studies on the cardioprotective effects of a novel class of antidiabetic agents have been published. A representative drug of interest is sodium–glucose cotransporter-2 (SGLT-2) inhibitor. Proposed pathophysiologic mechanisms of SGLT-2 inhibitors for cardioprotective effects are natriuretic effect, weight loss, reduced arterial stiffness, and improvement in ventricular loading conditions [37, 38]. Reducing cardiac preload and afterload results in lowering left ventricular structural and functional changes [39]. Prior to SGLT-2 inhibitor use, no other diuretic demonstrated clear cardiorenal protective effects in patients with diabetes although they reduced blood pressure or volume overload. None of the patients in our study were given any of these drugs because the safety of these drugs for patients with late stage of DMCKD has not yet been established.

This study includes several limitations. We could not confirm that LVDD and LVH were independently related to the duration of diabetes and/or diabetic kidney disease in the multiple linear regression model. Long-term effects of volume overload and uncontrolled blood pressure instability on the induction of cardiac impairments were not evaluated. As our patients were accompanied by complicated combinations of diabetes, hypertension, and kidney disease as well as medications, a clinically important point would be the longitudinal change of cardiac alterations in proportion to the progression of the disease. Despite these limitations, the strengths of our study include that all patients were free of intrinsic heart disease. In addition, analyses were adjusted for multiple confounding factors which were highly associated with OH/ECW, including cBMI, eGFR, hs-CRP, and serum calcium levels.

Conclusions

Our study suggests that strict volume controls are the cornerstone of effective treatment and prevention of the aforementioned cardiac impairments in patients with DMCKD5. Moreover, our study suggests that evaluation of the structural and functional cardiac abnormalities and volume status should be performed simultaneously in patients with early-stage DMCKD rather than only in patients with DMCKD5, in addition to intensive blood pressure and glycemic control, regardless of evident cardiovascular disease.

Comparison of demographics, serum chemistry, echocardiographic findings, and volume status between patients with and without left ventricular diastolic dysfunction.

(DOCX)

Click here for additional data file.

Comparison of demographics, serum chemistry, echocardiographic findings, and volume status between patients with and without left ventricular hypertrophy.

(DOCX)

Click here for additional data file.

Stepwise multiple linear regression of variables associated with E/e′ ratio and left ventricular mass index.

(DOCX)

Click here for additional data file.

14 May 2020

PONE-D-20-08628

Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis

PLOS ONE

Dear Prof. Han,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: All issues raised by reviewers are required.

==============================

We would appreciate receiving your revised manuscript by Jun 28 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please amend your current ethics statement to address the following concerns:

a) Did participants provide their written or verbal informed consent to participate in this study?

b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: .

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors,

it is an interesting manuscript that offers sound information about the effects of fluids overload on the heart in type2 DM.

it is well written and straightforward.

I have only a couple of observations:

In abstract you write that measurements were performed "on the same day". In methods it is not clear when the measurement were done (prior dyalisis). May you better explain it ? What the story before the day of measurement ? how long patients have suffered DM, how long the story of CKD ?

Another aspect needs some information. Volume status was calculated with bioimpedenzometry that is affected by BMI. You somehow corrected this, but it could be interesting to have the BMI of the evaluated patients and a discussion on the possible bias caused by BMI in the analysis. There were differences between patients with low and high BMI ?

minor: in § "assessment of the volume status" explanation of BIS and BCM are lacking.

Reviewer #2: In this paper, the authors want to investigate the association between fluid overload and left ventricular hypertrophy and left ventricular diastolic dysfunction in patient with DM type 2 and stage 5 chronic kidney disease. The manuscript is fairly well written, flow and readability are good. The rationale of the paper is clear and the analysis is sound. I consider the manuscript a good piece of research that improves the understanding of an interesting subject.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Edoardo De Robertis - University of Perugia, Italy

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

6 Jun 2020

We are uploading our response file .

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

19 Jun 2020

Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis

PONE-D-20-08628R1

Dear Dr. Kim,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors, thanks a lot to have evaluated the suggestions/observations raised and accordingly modified the text of the manuscript

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Edoardo De Robertis

13 Jul 2020

PONE-D-20-08628R1

Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis

Dear Dr. Kim:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Vincenzo Lionetti

Academic Editor

PLOS ONE